Business Wire·Nov 10, 2026, 8:05 AM ET

TriSalus Life Sciences Reports Third Quarter 2026 Results

TriSalus Life Sciences reported third quarter 2026 revenue of $12.9 million, representing an 11.3% increase compared to the same period in 2025.
The company revised its full-year 2026 revenue guidance to a range of $46 million to $48 million.
The FDA granted clearance for TriNav Advance, a device enabling Pressure-Enabled Drug Delivery (PEDD) to small distal vessels.
CMS finalized policies effective January 1, 2027, that increase the national Medicare payment rate for C8004 from approximately $11,794 to $20,910.
A new G-code (G0577) was established by CMS for office-based vascular embolization, creating a national payment of approximately $13,800 per procedure starting January 1, 2027.
Operating losses for the quarter were $7.7 million, a decrease from $9.0 million in the prior year period, driven by improved gross margins \& lower R\&D expenses.
Net loss attributable to common stockholders was $8.9 million, compared to $41.3 million in the prior year, largely due to preferred stock conversions in 2025.
Cash \& cash equivalents totaled $41.1 million as of September 30, 2026, following a $46 million equity offering earlier in the year.
The PROTECT registry reached its enrollment cutoff for the interim analysis of thyroid artery embolization, with data expected in the first quarter of 2027.
Gross margins improved to 86.2% in the quarter, up from 83.5% in the prior year, primarily due to reduced costs per TriNav unit.